Shots:

• Regenxbio has reported that the ATMOSPHERE trial evaluating RGX-314 is active and patient screening is ongoing. The study will enroll 300 patients across two RGX-314 dose arms vs ranibizumab- with anticipated initiation of patients dosing in Q1’21
• The second trial is expected to be similar in design to ATMOSPHERE with its expected initiation in H1’21. The company expects to submit a BLA based on these trials in 2024
• The company has completed enrollment of patients in Cohort 1 of the P-II AAVIATE study for wet AMD. Moreover- Regenxbio reported a new program RGX-202 for DMD with its expected IND filing in mid-2021

 ­ Ref: PRNewswire | Image: BioHealth Capital Region